News stories about Acorda Therapeutics (NASDAQ:ACOR) have trended very positive recently, according to Alpha One Sentiment Analysis. The research group, a unit of Accern, ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Acorda Therapeutics earned a news impact score of 0.69 on Alpha One’s scale. Alpha One also gave media coverage about the biopharmaceutical company an impact score of 50 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected AlphaOne Sentiment’s scoring:
- The Acorda Therapeutics (ACOR) Earns Daily News Sentiment Score of 0.20 (healthcaremenu.net)
- Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe (finance.yahoo.com)
- Acorda Therapeutics, Inc. (NASDAQ:ACOR) Trading Up – Short Interest Down by -5.31% – Highlight Press (highlightpress.com)
- ETFs with exposure to Acorda Therapeutics, Inc. : June 15, 2017 (finance.yahoo.com)
- Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 (finance.yahoo.com)
Several research analysts have weighed in on the stock. Cowen and Company restated an “outperform” rating and set a $35.00 price objective on shares of Acorda Therapeutics in a report on Wednesday, June 7th. J P Morgan Chase & Co set a $24.00 price objective on shares of Acorda Therapeutics and gave the stock a “hold” rating in a report on Tuesday, June 6th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $22.00 price objective on shares of Acorda Therapeutics in a report on Monday, April 3rd. Stifel Nicolaus restated a “buy” rating and set a $30.00 price objective on shares of Acorda Therapeutics in a report on Thursday, March 30th. Finally, Vetr upgraded shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating and set a $30.58 price objective on the stock in a report on Tuesday, March 14th. Six equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $25.62.
Acorda Therapeutics (NASDAQ:ACOR) traded up 0.88% during trading on Friday, reaching $17.25. 2,435,791 shares of the company traded hands. The firm’s market capitalization is $806.58 million. The company’s 50-day moving average price is $15.72 and its 200 day moving average price is $20.26. Acorda Therapeutics has a 52 week low of $13.60 and a 52 week high of $33.00.
Acorda Therapeutics (NASDAQ:ACOR) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.08. Acorda Therapeutics had a negative return on equity of 5.94% and a negative net margin of 10.13%. The business had revenue of $119.39 million during the quarter, compared to analyst estimates of $127.34 million. During the same quarter in the previous year, the firm earned $0.28 EPS. Acorda Therapeutics’s revenue was up 3.0% on a year-over-year basis. On average, equities research analysts expect that Acorda Therapeutics will post $1.98 EPS for the current year.
In other Acorda Therapeutics news, insider Andrew A. Hindman sold 7,704 shares of the business’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $15.75, for a total value of $121,338.00. Following the completion of the transaction, the insider now owns 46,123 shares of the company’s stock, valued at approximately $726,437.25. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.90% of the stock is currently owned by insiders.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with our FREE daily email newsletter.